Best GLP-1 Provider Methodology

CravingWise should score providers with the same published framework instead of choosing a winner from price or convenience alone. A practical weighting is 30% for clinical evaluation and ongoing care, 25% for medication and pharmacy transparency, 20% for total cost and contract terms, 10% for access and logistics, 10% for privacy practices, and 5% for advertising and disclosure quality. These weights are an editorial methodology, not a medical standard. Every review should identify the state and date checked and link to the provider’s official program, pricing, terms, privacy, and clinical-policy pages. Critical gaps should limit the final rating. A provider should not receive a top recommendation when CravingWise cannot confirm who delivers medical care, whether clinicians can legally treat patients in the relevant state, which medication pathway is offered, or which pharmacy dispenses the prescription. Unverified details should appear as “not confirmed,” not as assumptions. The methodology should also avoid combining FDA-approved brand-name medications and compounded products into one undifferentiated category. FDA states that compounded drugs are not FDA-approved and do not receive the same premarket review for safety, effectiveness, or quality. No provider itself is “FDA-approved,” and this methodology is not an FDA-cleared medical device.

The clinical score examines what happens before and after a prescription decision. Reviewers should identify the medical group providing care, the credentials of the clinician reviewing the intake, and whether the service explains where its clinicians are licensed. HHS notes that interstate telehealth rules vary and that legal pathways can include a full state license, reciprocity, a compact, or telehealth registration. A national marketing page therefore does not prove that a particular clinician can treat you where you are located. The initial process should be described accurately: questionnaire, asynchronous review, video visit, laboratory review, or another documented model. More steps do not automatically mean better care, but a fast checkout should not be treated as evidence of clinical quality. The continuing-care assessment should look for scheduled reassessment, refill review, a practical way to report side effects, response expectations for routine questions, and clear instructions for urgent concerns. Laboratory requirements should be reported as the provider states them because appropriate testing can depend on your history and clinical circumstances. A reviewer should not reward a service simply for requiring fewer questions or tests. This methodology evaluates access and transparency; it does not decide whether a medication is appropriate for you.

Medication scoring begins by recording exactly what the provider says it may prescribe and whether each option is an FDA-approved drug, an off-label use of an approved drug, or a compounded product. Eligibility and actual availability must remain conditional until a licensed clinician evaluates the patient. FDA’s current guidance says compounded drugs can address certain patient needs, but they are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality. Reviewers should not call a compounded product generic, equivalent to an approved drug, or FDA-approved. The telehealth company and dispensing pharmacy may be separate organizations, so both need to be identified. CravingWise should record the pharmacy’s legal name and location when disclosed, then direct readers to verify its license with the relevant state board. FDA BeSafeRx says safer online pharmacies require a valid prescription, provide a US address, have a state-licensed pharmacist available, and hold appropriate state licensure. If the provider will not name the pharmacy until after purchase, that limitation belongs prominently in the review. Pharmacy accreditation or outsourcing-facility registration can add context, but neither should be described as FDA approval of the finished compounded medication. Medication and pharmacy relationships must be rechecked whenever the review is updated.

The cost score uses comparable categories instead of the largest advertised number. For each provider, CravingWise should record the initial consultation or intake fee, recurring membership, medication, required or potential laboratory work, supplies, shipping, taxes, and any separately billed follow-up. It should calculate the first month, the expected ongoing month, and the total contractual commitment when official terms make that possible. When medication cost depends on the drug, dose, insurance decision, or pharmacy, the review should show a range or mark the amount unconfirmed rather than manufacture one total. Current official provider pages demonstrate why this matters. Ro states that its Body membership and medication are billed separately, while WeightWatchers states that GLP-1 medication is not included in its Med+ membership. Their official pages also describe promotional pricing, prepayment options, or commitment periods. These examples support the methodology but are not permanent prices or endorsements. Terms should be checked for automatic renewal, cancellation timing, refunds, missed visits, refill timing, and what happens when a clinician does not prescribe treatment. Insurance assistance must be described precisely: checking benefits, filing prior authorization paperwork, or appealing a denial does not guarantee coverage. Promotional and renewal terms should receive equal visibility in every review.

Privacy is scored separately from clinical care because a provider may operate a consumer website, mobile app, affiliated medical group, pharmacy, and analytics stack under different notices. Reviewers should read both the general privacy policy and the clinic’s Notice of Privacy Practices. Depending on the service, collected information can include identity and contact details, payment data, location, browsing or device identifiers, medical history, diagnoses, medication requests, height and weight, uploaded photographs, laboratory results, insurance information, and messages. Disclosures may involve affiliated medical groups, pharmacies, laboratories, insurers, payment processors, service vendors, analytics providers, or advertising partners, subject to the applicable policy and law. Do not treat “HIPAA-compliant” as a complete privacy answer. HHS explains that HIPAA protects information handled by covered entities and business associates, but usually does not protect personal app data, search history, location information, or other consumer data outside that relationship. The methodology should check targeted-advertising disclosures, opt-out controls, retention language, deletion rights, and whether clinical information is clearly separated from marketing data. Advertising receives a separate evidence check. FTC guidance says health-benefit and safety claims must be truthful, nonmisleading, and supported by competent and reliable scientific evidence. Testimonials, paid endorsements, and dramatic results should never substitute for provider-specific evidence.

This framework is useful when you are comparing licensed US telehealth programs and want a consistent way to examine clinical access, medication sourcing, cost, contracts, privacy, and marketing. It is especially helpful when two providers advertise similar drug names but use different medical groups, pharmacies, support models, or billing structures. The score should help you narrow a shortlist; it should not tell you that one provider is medically appropriate for everyone. You should look beyond an online ranking when you need an in-person examination, coordinated management of complex or unstable conditions, integration with an established care team, or immediate help. A telehealth subscription is not emergency care. You should also look elsewhere when a service will not identify who provides care, does not require a valid prescription, hides the dispensing pharmacy, or makes the full commitment difficult to understand. Before paying, verify the clinician and pharmacy for your state, read the current terms and privacy notices, and ask what communication remains available if you cancel or transfer care. Educational only: this methodology does not provide diagnosis, treatment, prescribing, or dosing guidance. Medication decisions and changes belong with a licensed clinician who understands your history, other medications, and individual risks.